The nonclinical ADME (adsorption, distribution, metabolism, and excretion) studies employed during drug development are dependent on the regulatory expectations and the changing development focus from nonclinical to clinical issues. These evolving issues necessitate that the development goals for ADME studies also change during the development process. The rationale for these goal changes and their impact on the timing and design of the ADME studies are discussed in the context of drug development at Glaxo Inc. The progress in the technology and knowledge in drug metabolism and in biology provide new opportunities for pharmaceutical companies in predicting drug toxicities relevant to humans. Two case examples are discussed to illustrate this opportunity.
INTRODUCTION
Those of us working in drug development are always seeking the proper balance between the science and the business forces that define how effective our company is in bringing new medicines to the patient (Fig. 1 ). Too much business focus and the pipeline of new products withers, whereas too much science and no products ever make it to the marketplace. At Glaxo, the goals, design, and timing of nonclinical drug metabolism studies are driven by regulatory expectations and the strategic organization of the company's drug development program. In this article, I will describe how Glaxo currently has defined its own balance point between business and science, as this provides a significant part of the rationale that drives our nonclinical drug metabolism program. I will also take the opportunity to describe the status and future opportunities currently becoming available because of the progress in drug metabolism and biology. EXPLORATORY DEVELOPMENT At Glaxo, drug development is philosophically and organizationally separated into 2 phases: exploratory and full development (Fig. 2) . Exploratory development is viewed as an extension of the research process rather than an early phase of drug development. During this phase, the goal is the most rapid attainment of preclinical and early clinical milestones that demonstrate the clinical potential of a new discovery. Because most drug candidates are eliminated during this phase, it is designed to be a screening process conducted to demonstrate the therapeutic potential with the minimum investment. Another way to view this is as a desire to be as quick as possible in determining the clinical promise of a compound and to also be quick in dropping a compound that does not show promise. Because exploratory development is viewed as an extension of the research process of compound selection, it is conducted at the site in which the drug candidate was discovered.
Given the business objective of rapid selection during exploratory development, what are the typical decision points? Establishing adequate safety coverage for the human studies and determining whether or not there is evidence for therapeutic activity in the clinic are 2 primary objectives of exploratory development. Both the tolerability and efficacy in humans must be established. Nonclinical ADME (adsorption, distribution. metabolism, and excretion) studies are used to link the animal pharmacology and toxicology studies to humans. The goals of ADME studies in exploratory development are as follows: Quantitatively defining the exposure coverage relative to humans that is achieved during the toxicology studies in animals. . Validating the appropriateness of the animal species used in the toxicology studies to humans. . Establishing the starting dose that should be employed in the Phase I clinical program.
To achieve these ADME goals, a bioanalytical assay is developed and validated and a radiolabeled derivative of the compound is produced. Both assay development and synthesis of the radiolabeled compound are first-priority objectives at the time a compound is accepted into exploratory development. Both provide the foundation on which pharmacokinetic, excretion-balance, and metabolite profiling data are based. Because both are so vital to the rapid achievement of the exploratory development ADME goals, both resources are in the drug metabolism department at Glaxo.
Exposure Coverage
The pharmacokinetics of the compound during pharmacology studies and during the dose-ranging and 1-mo toxicology studies are determined to provide an objective measure of the multiples of human exposure coverage provided by the toxicology studies. Cmax and area under the curve (AUC) determinations are used as measures of exposure. Although clinical determination of the maximum tolerated dose is usually employed in the United States to establish the top dose in humans, Cmax and AUC values at the NOEL in the toxicology animals are used to guide the maximum exposure limits for compounds demonstrating irreversible or unacceptable toxicology potential. The strong collaborative relationships among drug metabolism, pharmacology, and toxicology usually produce study designs with appropriate blood sampling to obtain kinetic information. 
Validation of Animals Used in Toxicology Studies
Radiolabeled compounds are employed with the 2 species used in the toxicology studies. This provides a quantitative, chromatographic view of the range of metabolites produced that can be compared to the metabolic profile from human studies to ensure that the toxicology animal species were exposed to the same range of metabolites as humans. In addition, excretion-balance data are also obtained from these studies to define the major excretory pathways and to verify the completeness of elimination of the compound.
Starting Dose Selection
Setting the starting dose for Phase I is an objective of exploratory development. This is based on interspecies extrapolation of pharmacokinetic data for compounds cleared principally by renal elimination while a fraction of the NOEL is usually employed for drugs cleared principally by metabolism. Although renal excretion has been found to be scalable among species, the route and rate of drug metabolism processes have not been found to be as predictable among species. FULL DEVELOPMENT After a candidate demonstrates its therapeutic potential in the clinic, a decision must be made to move the compound into full development (Fig. 2) . Unlike exploratory development, in which the operating assumption is that the compound will fail, during full development the assumption is that the candidate will succeed. Consequently, in contrast to exploratory development, where speed is achieved through a minimization process, speed is achieved in full development through the addition of more resources. Thus, development is expanded to include international resources.
The overall objective of full development is to progress the compound as rapidly to market as possible. The primary goals of ADME studies are as follows:
. Completing metabolism studies to validate the relevance of animals employed in the toxicology studies to humans. Definitive structural assignments of all the major metabolites produced in the toxicology animals and in humans are determined.
Demonstrating the systemic exposure of animals in the safety assessment studies to support conducting longer term and special population clinical trials. The main toxicology studies supported by pharmacokinetic studies are the reproductive toxicology, 6and 12-mo, and oncogenicity studies.
Reproductive Toxicology Studies
During the reproductive toxicology studies, drug exposure to both the mother and embryo are verified. Usually, C~_ and Cmin values are determined on day 1 and during the steady-state drug blood level phase achieved during multiple dosing for Segment I and II studies. In addition, placental transfer and excretion-balance studies are conducted to confirm exposure of the embryo and the elimination of drugrelated material from the animal. Whole-body autoradiography of the mother and embryo are conducted during organogenesis (day 12). The metabolic profile is also determined on pregnant rats (day 12) to determine the effect of pregnancy on drug metabolism.
6-and 12-Mo Toxicology Study
Periodic sampling through the 12-mo dosing period is conducted to confirm drug exposure during the length of the study. Pharmacokinetics are calculated to determine the effect of age on drug kinetics.
Oncogenicity Studies
Oncogenicity studies are usually the first occasion for employing the mouse for toxicological evaluation. A single-dose pharmacokinetics study is conducted to characterize the pharmacokinetics in the mouse. Pharmacokinetic studies are also conducted during the dose-ranging portion for the oncogenicity studies. This provides a means for selecting doses and defining appropriate sampling times for the main study. During the main oncogenicity study, periodic monitoring of the serum concentrations of drug is conducted to confirm continued exposure.
Special ADME Studies
One of the most significant issues in the therapeutic use of drugs is selecting the correct dose given the variability in response among patients. Some of this variability is due to the wide range in the oral bioavailability and metabolic clearance among humans. Interindi~-idual variability in the expression of the activity of individual cytochrome P-450 en-zymes undoubtedly is responsible for much of this variability. Both the wide variability in the quantities of individual enzymes among subjects and genetic polymorphism, in which a fraction of the population is genetically devoid of individual enzymes. are known to contribute to the diversity in metabolic clearance within the human population (4, 5. 11).
Variability in drug response may be compounded further when drugs are coadministered. The action of one drug to either increase or decrease the metabolic clearance of a second drug can result from drug interactions with the drug-metabolizing enzymes. Even natural product dietary components can produce clinically relevant drug interactions (6) . These drug-drug interactions can profoundly influence the variability in systemic drug exposure among people taking the same dose. For this reason, there is increasing interest from pharmaceutical companies and regulatory authorities on the enzymology of drug-metabolizing enzymes and on the potential for drug-drug interactions caused by these enzymes. At Glaxo, some recent experiences illustrate this fact:
A Food and Drug Administration (FDA) postmarketing request to identify specific human cytochrome P-450 enzymes responsible for the metabolism of ondansetron. Recombinant enzymes, genotyped human liver bank and probe substrate assays, and specific inhibitors provided a means for answering this question with in vitro enzyme systems.
. FDA and Swiss regulatory authorities' requests for information on the role of monoamine oxidase in the metabolism of sumatriptan.
An FDA request for identification of enzymes involved in the metabolism of salmeterol. Human liver preparations were employed to respond to this request.
. The induction of cytochrome P-450 1 A in animals, resulting in a targeted clinical study to evaluate this potential in humans.
FUTURE OPPORTUNITIES FOR NONCLINICAL DRUG METABOLISM
Advances during the last 20 yr on the accessibility of human tissues. the expression of human forms ofcytochrome P-450. anal) tical and structural instrumentation. and the increase in knowledge on the role of drug metabolism in drug-induced toxicities now make it often possible to identify the potential for important drug-drug interactions with in vitro ADME studies. Two case examples provide a means for describing the opportunities that have arisen from advances in drug metabolism and biology. 
Terfenadine
Approximately 20 yr ago, terfenadine was undergoing development as a new nonsedating antihistamine. It was recognized at that time that metabolism was required (Fig. 3) to convert the inactive parent compound into the carboxylic acid derivative responsible for terfenadine's antihistamine activity (7) . It was also known that the metabolism of terfenadine was facile and essentially complete during its first passage through the liver following oral absorption. This occurred in all the toxicology animals and in humans. What was not recognized was that some drugs, notably imidazole antifungal agents, could cause inhibition of the cytochrome P-450 3A4 enzyme, which was responsible for the metabolism of terfenadine. This inhibition and the resulting accumulation of terfenadine could result in the production of life-threatening ventricular arrhythmias by a compound that had undergone all the preclinical and clinical safety assessment evaluations.
Recent retrospective investigations with in vitro systems by clinical pharmacologists from the Uniformed Services University, the FDA, and Georgetown University, following the initial report of torsades de pointes in a patient taking terfenadine in combination with ketoconazole, have clearly demonstrated the utility of such studies in explaining this drug-drug interaction (8, 12) . Today, these techniques can provide a means for predicting, rather than explaining, the consequences of drug interactions with many human drug-metabolizing enzymes. This technology permits us to prospectively determine the metabolites that will be formed in clinical studies and anticipate the potential for drug interactions caused by the inhibition or induction of the enzymes responsible for drug clearance.
Terfenadine exemplifies a case in which drug metabolism eliminates the potential for an adverse drug reaction caused by the parent compound. More commonly, however, toxicities result from the production of toxic metabolites. The pulmonary toxicity produced by 4-ipomeanol is such an example. This research also illustrates the scientific progress achieved in the past 20 yr that now makes it often possible to understand and predict drug toxicities that are caused by metabolites. 
4-Ipomeanol
The observation of severe pulmonary disease in animals ingesting moldy sweet potatoes led Boyd and colleagues to a series of studies that implicated the natural product 4-ipomeanol ( Fig. 4) as the causative agent (2) . These studies, conducted in the early 1970s, led Boyd to further conclude that metabolism of 4-ipomeanol to highly reactive metabolites was required to cause the necrotic lesions that were observed in the target organ nonciliated terminal bronchiolar clara cells ( 1 ) .
The identity of the cytochrome P-450 4B enzyme and its localization in Clara cells implicated this specific enzyme in the production of highly reactive, toxic metabolites (3, 9) . Molecular biology techniques have very recently clearly confirmed the causative role of cytochrome P-450 4B in the metabolic activation and cellular toxicity of 4-ipomeanol (10) . These methods were used to construct cellular systems that contained cytochrome P-450 4B 1 and that manifested the metabolism and toxicity observed in animals. The extension of this technology to the transfection of mammalian cells with the complementary DNAs encoding specific human drug-metabolizing enzymes is nearing reality.
CONCLUSION
The overall goal for ADME studies in toxicology studies is to verify the relevance to humans of drug and metabolite exposure in animals. The pharmacokinetics obtained from these and the pharmacology studies often permit the estimation of a safe starting dose in humans. Although the overall goal for ADME studies is common among pharmaceutical companies, the design and timing are to a large extent dependent on the operating philosophy of the individual company. The operational distinction between exploratory and full development has been described because it drives the nature of the ADME studies as well as the other preclinical activities at Glaxo.
The progress in our knowledge of drug metabolism and the advances in analytical and molecular biological technologies have created new opportunities for drug metabolism and toxicology. Twenty yr ago, there was no knowledge about the specific human enzyme responsible for the metabolism of terfenadine or the cardiovascular toxicity that could arise as a consequence of the inhibition of this enzyme. Research has closed this gap and. as the research on 4-ipomeanol has shown, the potential now exists to produce cellular systems that can be used not only to predict the metabolic processes but also the toxicologic consequences relevant to humans. The application of these techniques to prospectively assess the potential for drug toxicities caused by drug metabolism is an important opportunity for both drug metabolism and toxicology.
